US20090232914A1 - Pharmaceutical composition for treating depression and method for preparation thereof - Google Patents

Pharmaceutical composition for treating depression and method for preparation thereof Download PDF

Info

Publication number
US20090232914A1
US20090232914A1 US11/909,087 US90908705A US2009232914A1 US 20090232914 A1 US20090232914 A1 US 20090232914A1 US 90908705 A US90908705 A US 90908705A US 2009232914 A1 US2009232914 A1 US 2009232914A1
Authority
US
United States
Prior art keywords
extract
weight
pharmaceutical composition
jujuba
ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/909,087
Other languages
English (en)
Inventor
Zuoguang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHI YUH-FEN
BEIJING WONNER BIOTECH Ltd Co
Original Assignee
BEIJING WONNER BIOTECH Ltd Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING WONNER BIOTECH Ltd Co filed Critical BEIJING WONNER BIOTECH Ltd Co
Assigned to BEIJING WONNER BIOTECH LTD. CO., ZHANG, ZUOGUANG, CHI, YUH-FEN reassignment BEIJING WONNER BIOTECH LTD. CO. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZHANG, ZUOGUANG
Publication of US20090232914A1 publication Critical patent/US20090232914A1/en
Assigned to BEIJING WONNER BIOTECH, LTD. CO., CHI, YU-FEN, ZHANG, ZUOGUANG reassignment BEIJING WONNER BIOTECH, LTD. CO. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE YUH-FEN CHI SHOULD READ YU-FEN CHI PREVIOUSLY RECORDED ON REEL 019845 FRAME 0957. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Assignors: ZHANG, ZUOGUANG
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a pharmaceutical composition.
  • the present invention relates to a pharmaceutical composition for treating depression as the main effect.
  • the present invention further relates to a preparation method of the pharmaceutical composition for treating depression as the main goal.
  • Depression is a common disease. According to statistics, about 25% females in the global population had been experiencing depression in their lives, and about 10% males had been experiencing depression (referring to Morden Psychology written by Ch'un-Hsing Chang). World Health Organization (WHO) published, “The incidence of depression in the world is about 11%. At present, about 340 million psychological depressed patients are in the world, and the number is increased. The investigation is found that the depression will be increased to be the number two common disease in the world from now on to 20 years later.”
  • anti-depression pharmaceuticals in the domestic and overseas markets consist mainly selective serotonin reuptake inhibitors (SSRIs), such as Prozac (fluoxetine hydrochloride), Paxil (Paroxetine or paroxetine hydrochloride) and Zoloft (sertraline hydrochloride), etc.
  • SSRIs selective serotonin reuptake inhibitors
  • Prozac fluoxetine hydrochloride
  • Paxil Paroxetine or paroxetine hydrochloride
  • Zoloft sertraline hydrochloride
  • the purpose of the present invention provides a herbal pharmaceutical composition for anti-depression as the main effect. It can be used as pharmaceuticals or health food for improving the depression.
  • a pharmaceutical composition for treating depression at least comprises one of the following compositions of raw materials: (A) 4 ⁇ 18 parts by weight of a ginseng and 3 ⁇ 14 parts by weight of a liquorice; (B) a ginseng extract extracted from 4 ⁇ 18 parts by weight of the ginseng and a liquorice extract extracted from 3 ⁇ 14 parts by weight of the liquorice; (C) 4 ⁇ 18 parts by weight of the ginseng and the liquorice extract extracted from 3 ⁇ 14 parts by weight of the liquorice; and (D) a ginseng extract extracted from 4 ⁇ 18 parts by weight of the ginseng and 3 ⁇ 14 parts by weight of the liquorice.
  • the pharmaceutical composition further comprises one of 3 ⁇ 14 parts by weight of a jujuba and a jujuba extract extracted from 3 ⁇ 14 parts by weight of the jujuba, wherein the jujuba extract is one of a jujuba water extract and a jujuba ethanol extract.
  • the pharmaceutical composition further comprises one of 4 ⁇ 8 parts by weight of a jujuba and a jujuba extract extracted from 4 ⁇ 8 parts by weight of the jujuba.
  • the composition (A) of the raw materials is formed by 7 ⁇ 11 parts by weight of the ginseng and 4 ⁇ 8 parts by weight of the liquorice.
  • the ginseng extract of the composition (B) of the raw materials is extracted from 7 ⁇ 11 parts by weight of the ginseng and the liquorice extract thereof is extracted from 4 ⁇ 8 parts by weight of the liquorice.
  • the pharmaceutical composition may comprise a pharmacologically acceptable additive, or none at all.
  • the pharmaceutical composition is processed into one selected from a group of a powder, a capsule, a tablet, and a pill.
  • the ginseng extract is one of a ginseng water extract and a ginseng ethanol extract
  • the liquorice extract is one of a liquorice water extract and a liquorice ethanol extract.
  • a pharmaceutical composition for treating the depression comprises: a ginseng extract extracted from 3A ⁇ 10A parts by weight of a ginseng and having B % content of a ginsenoside, wherein a multiplication product of B and A is 20 ⁇ 40, and A is ranged between 0.2 and 40; and 0.2C ⁇ 0.8C part by weight of a glycyrrhizically related acid having D % purity, wherein a multiplication product of D and C is 80 ⁇ 98, and C is ranged between 0.8 and 98.
  • the ginseng is one of a ginseng water extract and a ginseng ethanol extract
  • the glycyrrhizically related acid is one of a glycyrrhizic acid and a glycyrrhetic acid.
  • the ginseng ethanol extract comprises 20 ⁇ 40% content of the ginsenoside, and the purity of the glycyrrhizically related acid is 80 ⁇ 98%.
  • the pharmaceutical composition further comprises a jujuba extract extracted from 0.05E ⁇ 0.2E part by weight of a jujuba and having F % content of a jujuba cyclic adenosine monophosphate (cAMP), wherein a multiplication product of F and E is 0.5 ⁇ 3, E is ranged between 0.005 and 3, and the jujuba extract is one of a jujuba water extract and a jujuba ethanol extract.
  • cAMP a jujuba extract extracted from 0.05E ⁇ 0.2E part by weight of a jujuba and having F % content of a jujuba cyclic adenosine monophosphate (cAMP), wherein a multiplication product of F and E is 0.5 ⁇ 3, E is ranged between 0.005 and 3, and the jujuba extract is one of a jujuba water extract and a jujuba ethanol extract.
  • the jujuba ethanol extract comprises 0.5 ⁇ 3% content of the jujuba cAMP.
  • the ginseng extract is an ethanol extract extracted from 4 ⁇ 6 parts by weight of the ginseng and has 25 ⁇ 35% content of ginsenoside
  • the glycyrrhizically related acid is 0.3 ⁇ 0.5 part by weight of a glycyrrhetic acid having 85 ⁇ 95% purity
  • the pharmaceutical composition further comprises a jujuba ethanol extract extracted from 0.08 ⁇ 0.12 part by weight of a jujuba and having 0.8 ⁇ 1.2% purity of a jujuba cAMP.
  • the pharmaceutical composition may comprise a pharmacologically acceptable additive, or none at all.
  • the pharmaceutical composition is processed into one selected from a group consisting of a powder, a capsule, a tablet, and a pill.
  • a preparation method of a pharmaceutical composition comprises steps of: (1) decocting 4 ⁇ 18 parts by weight of a ginseng in 60 ⁇ 77% concentration of an ethanol solution to obtain a first extract; (2) decocting 4 ⁇ 18 parts by weight of a liquorice in a water to obtain a second extract; and (3) mixing and sifting the first extract and the second extract to obtain the pharmaceutical composition.
  • the preparation method further comprises a step of: (4) extracting 3 ⁇ 14 parts by weight of a jujuba in 60 ⁇ 75% concentration of the ethanol solution to obtain a third extract, and adding the third extract into the pharmaceutical composition.
  • a preparation method of a pharmaceutical composition comprises a step of: (1) mixing 3 ⁇ 10 parts by weight of a ginseng extract having 20 ⁇ 40% content of a ginsenoside with 0.2 ⁇ 0.8 part by weight of a glycyrrhizically related acid having 80 ⁇ 98% purity to obtain a pharmaceutical composition.
  • the preparation method further comprises a step of: (2) compounding a ⁇ -cyclodextrin with a jujuba extract extracted from 0.05 ⁇ 0.2 part by weight of a jujuba and having 1% jujuba cyclic adenosine monophosphate (cAMP) to obtain a jujuba extract compound, and adding the jujuba extract compound into the pharmaceutical composition.
  • a ⁇ -cyclodextrin with a jujuba extract extracted from 0.05 ⁇ 0.2 part by weight of a jujuba and having 1% jujuba cyclic adenosine monophosphate (cAMP)
  • the ginseng contains adenylate cyclase (AC) for stimulating adenosine, and the phosphodiesterase inhibitor. Both of the adenylate cyclase and phosphodiesterase inhibitor have synergism and collectively increase the cAMP in the cells.
  • the phenylalanine is promoted by the ginseng to increase the synthesis of dopamine (DA) and norepinephrine (NE) through the blood-brain barrier, and thus the concentrations of the dopamine and norepinephrine are increased.
  • DA dopamine
  • NE norepinephrine
  • Liquorice The glycyrrhizic acid and glycyrrhetinic acid in liquorice are strong cAMP phosphodiesterase inhibitors.
  • the cAMP degradation is decreased by inhibiting cAMP phosphodiesterase, and then the usage of cAMP in the central nervous system is increased.
  • Jujuba contains a large amount of cAMP-like materials.
  • the extrinsic non-hydrated cAMP can be participated in the metastasis of cAMP in the body and be analogized the enzyme's function, and the cAMP in the cells is increased.
  • the ginseng, liquorice and jujuba in the pharmaceutical composition of the present invention are paired and acted collectively by stimulating the adenylate cyclase to increase the concentration of cAMP in brain cells, and by inhibiting the cAMP phosphodiesterase to decrease the degradation of cAMP and increase the usage of cAMP.
  • the concentration and activity of the increased cAMP can increase the synthesis and release of neurotransmitters, such as norepinephrine, etc. (referring to Volume One, Principles of Neurosciences regarding the related description of the cAMP to the synthesis of catecholamine (CA)). This process is the mechanism of the modern pharmacology for anti-depression in this composition.
  • compositions of the present invention are described as follows.
  • Composition 1 4 ⁇ 18 parts by weight of the ginseng and 3 ⁇ 14 parts by weight of the liquorice.
  • the preferred composition of the medicine prepared by the raw materials of the weight ratio is described as follows: 9 parts by weight of the ginseng and 6 parts by weight of the liquorice.
  • Composition 2 4 ⁇ 18 parts by weight of the ginseng, 3 ⁇ 14 parts by weight of the liquorice, and 3 ⁇ 14 parts by weight of the jujuba.
  • the preferred composition of the medicine prepared by the raw materials of the weight ratio is described as follows: 9 parts by weight of the ginseng, 6 parts by weight of the liquorice, and 6 parts by weight of the jujuba.
  • Composition 3 3 ⁇ 10 parts by weight of the ginseng ethanol extract (containing 20 ⁇ 40% of the ginsenoside), 0.2 ⁇ 0.8 part by weight of the glycyrrhetinic acid (80 ⁇ 98% purity), and 0.05 ⁇ 0.2 part by weight of the jujuba ethanol extract (containing 0.5 ⁇ 3% of the jujuba cAMP).
  • composition 3 the preferred composition of the medicine prepared by the raw materials of the weight ratio is described as follows: 5 parts by weight of the ginseng ethanol extract (containing 30% of the ginsenoside), 0.4 part by weight of the glycyrrhetinic acid (90% purity), and 0.1 part by weight of the jujuba ethanol extract (containing 1% of the jujuba cAMP).
  • the pulverized substance of the ginseng and liquorice is directly used according to the dictated weight ratio of the composition, and the pharmaceutical composition is directly prepared.
  • Another pharmaceutical composition is prepared by adding the jujuba dry powder on the basis of this pharmaceutical composition.
  • the component weight ratio of the composition either a dry powder of the raw material is adopted, and the water extract or the ethanol extract of the other component is added to prepare the pharmaceutical composition of the present invention, or a water extract or an ethanol extract of the raw material is adopted, and the dry powder of the other component is added to prepare the pharmaceutical composition of the present invention.
  • the preparation method of the pharmaceutical composition of the present invention includes:
  • the preferred composition of the medicine is 9 parts by weight of the ginseng and 6 parts by weight of the liquorice in the above method.
  • jujuba Three (3) 14 parts by weight of the jujuba (the preferred composition of the medicine is 6 parts by weight) is further added and decocted in the ethanol solution in Method 1, is then separated and purified by chromatography, and is compounded with the ⁇ -cyclodextrin to obtain the jujuba extract compound.
  • the jujuba extract compound is mixed and pulverized with the first extract and the second extract to obtain the pharmaceutical composition 2 of the present invention.
  • each composition in the above method is: 0.1 part by weight of the jujuba extract having 1% of the jujuba cAMP (compounded with 9 parts by weight of the ⁇ -cyclodextrin), 5 parts by weight of the ginseng extract having 30% of the ginsenoside, and 0.4 part by weight of the glycyrrhetinic acid having 90% purity.
  • the resolving scheme of the herbal pharmaceutical composition of the present invention is to cooperate with the treating mechanism of modern medicine and pharmacology with regards to depression, so as to investigate and develop a herbal pharmaceutical composition for the treatment of depression as the main goal based on the principles of Chinese medicine.
  • the characteristics are that all the raw materials are pharmaceutical that doubles as food, the combinations of pharmaceuticals are simple (only 2 ⁇ 3 pharmaceuticals), the function and mechanism are defmite (conforming with the function and mechanism of modern pharmacology), the effects and ingredients can be quantified, and the curative effect is significant and safe.
  • This kind of plant derived pharmaceuticals that doubles as food has no toxicity or side effects. It can be used as pharmaceuticals or health food for treating depression and be taken on a long term basis.
  • the pharmaceutical composition of the present invention can be administrated as the unit dose formula, and the way of administration can be intestinal or non-intestinal, such as oral administration, etc.
  • the media include tablet, capsule, pill, roll, powder, solution, suspension, emulsion, and particle, etc. It can be prepared as immediate release, sustained release, controlled release, and microsphere delivery system.
  • each carrier for one skilled in the art can be widely used.
  • the examples regarding to the carriers are the dilutents and the absorbents, i.e. starch, dextrin, calcium sulphate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, and aluminum silicate, etc.
  • the further examples regarding to the carriers are the wetting agents and the bonding agents, i.e. water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, arabic mucilage, gelatin, sodium carboxymethylcellulose, lac, methyl cellulose, potassium phosphate, and poly vinyl pyrrolidone, etc.
  • the further examples regarding to the carriers are the lysis agents, i.e. dried starch, alginate, agar, laminaran, sodium hydrogencarbonate, citric acid, calcium carbonate, polyoxyethylenesorbitanalkylester, sodium dodecyl-sulfonate, methyl cellulose, and ethyl cellulose, etc.
  • the further examples regarding to the carriers are the lysis inhibitors, i.e. sucrose, tristearyl glycerol, cocoa butter, and hydrogenated oil, etc.
  • the further examples regarding to the carriers are the absorbefacients, i.e. quaternary ammonium salt, and sodium dodecyl-sulfonate, etc.
  • the further examples regarding to the carriers are the lubricants, i.e. talcum powder, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, and polyethylene glycol, etc.
  • the tablet is further produced as the coating tablet, i.e. sugar coating tablet, film coating tablet, intestine-dissolving coating tablet, bi-layer tablet, and multi-layer tablet.
  • each carrier for one skilled in the art can be widely used.
  • the examples regarding to the carrier are the dilutents and the absorbents, i.e. glucose, sucrose, starch, cocoa butter, hydrogenated vegetable oil, poly vinyl pyrrolidone, Gelucire, kaolin, talcum powder, etc.
  • the further examples regarding to the carrier are the bonding agents, i.e. arabic gum, tragacanth gum, gelatin, ethanol, honey, liquid sugar, rice slurry, and batter, etc.
  • the further examples regarding to the carrier are the lysis agents, i.e.
  • each carrier for one skilled in the art can be widely used.
  • the examples regarding to the carrier are polyethylene glycol, lecithin, cocoa butter, high alcohol, high alcohol ester, gelatin, semisynthetic glyceride, etc.
  • the pharmaceutical composition or the extract of the present invention are mixed with each carrier described above, and the mixtures obtained from these methods are added into the hard gelatin capsules or the soft capsules.
  • the pharmaceutical composition and the extract of the present invention can be prepared as the microcapsule, and be suspended in aqueous medium to form the suspension. This can be applied to be added into hard capsules.
  • coloring agents can be added into the pharmaceutical composition.
  • FIG. 1 is a flowchart diagram showing a preparation method of a pharmaceutical composition in accordance with a first preferred Embodiment of the present invention
  • FIG. 2 is a flowchart diagram showing a preparation method of a pharmaceutical composition in accordance with a second preferred Embodiment of the present invention.
  • FIG. 3 is a flowchart diagram showing a preparation method of a pharmaceutical composition in accordance with a third preferred Embodiment of the present invention.
  • FIG. 1 is a flowchart diagram showing a preparation method of a pharmaceutical composition in accordance with a first preferred Embodiment of the present invention.
  • FIG. 1 adopts the method which one is skilled in the art.
  • Nine (9) kg of the ginseng ( 101 ) is decocted in ethanol solution of 75% purity, and then is separated and purified by column chromatography to obtain the first extract ( 102 ).
  • the first extract has 40% of ginsenoside.
  • Six (6) kg of the liquorice ( 103 ) is decocted in the water solution, and then filtered, concentrated, and dried to obtain the second extract ( 104 ).
  • the first extract is mixed with the second extract, and then is pulverized to obtain the first pharmaceutical composition of the present invention ( 105 , 106 , 107 , and 108 ).
  • FIG. 2 is a flowchart diagram showing a preparation method of a pharmaceutical composition in accordance with a second preferred Embodiment of the present invention.
  • 9 kg of the ginseng ( 201 ) is decocted in 60% of ethanol solution, and then separated and purified by column chromatography to obtain the first extract ( 202 ).
  • Six (6) kg of the liquorice ( 203 ) is decocted in water solution, and then filtered, concentrated, and dried to obtain the second extract ( 204 ).
  • Six (6) kg of the jujuba ( 205 ) is decocted in 75% of ethanol solution, and then separated and purified by column chromatography to obtain the third extract.
  • the third extract is compounded with 9 parts by weight of the ⁇ -cyclodextrin to obtain the extract compound ( 206 ).
  • the first extract, the second extract, and the extract compound of the third extract are mixed and pulverized to obtain the second pharmaceutical composition of the present invention ( 207 , 208 , 209 , and 210 ).
  • FIG. 3 is a flowchart diagram showing a preparation method of a pharmaceutical composition in accordance with a third preferred Embodiment of the present invention.
  • One (1) g of the jujuba extract (having 1% of jujuba cAMP) ( 302 ) is compounded with 9 g of ⁇ -cyclodextrin to obtain 10 g of extract compound ( 303 ).
  • This pharmaceutical composition is prepared by adopting the same method that of Embodiment 4. The difference is adopting 18 kg of ginseng and 14 kg of liquorice.
  • the pharmaceutical pills are prepared by the method adopted by one skilled in the art.
  • the pharmaceutical soft capsules are prepared by the method adopted by person skilled in the art.
  • the pharmaceutical of the Embodiment 3 of the present invention is provided by Beijing Wonner Biotech Ltd. Co.
  • the depression-relieving pill is the product of Zhengzhou Yumi Medicines Co. Ltd.
  • Paroxitine (Paxil) is the product of Zhong Mei Tianjin Smith Kline pharmaceuticals Co. Ltd.
  • Mouse tail-hanging experiment The mouse's tail (near to the tail end for 1 cm) is taped on the 5 cm of the wood strip of the high mountain platform and hanged up for 6 minutes. The time of non-movement of the mouse for the last 5 minutes is recorded.
  • the pharmaceutical of the Embodiment 3 of the present invention is provided by Beijing Wonner Biotech Ltd. Co.
  • the depression-relieving pill is the product of Zhengzhou Yumi Medicines Co. Ltd.
  • Paroxitine (Paxil) is the product of Zhong Mei Tianjin Smith Kline pharmaceuticals Co. Ltd.
  • anal temperature (abbreviated as anal temp.) is determined, and then 2 mg resetpine per kg of the body weight is taken by intraperitoneal injection. After injecting the resetpine for 2, 3, 4, 5, 6 and 7 hours respectively, the anal temperature of the mice are determined.
  • the variance analysis calculation and the p-value compared with the control of the experimental result are calculated by using SPSS 11.5 analytic software.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
US11/909,087 2005-03-25 2005-10-31 Pharmaceutical composition for treating depression and method for preparation thereof Abandoned US20090232914A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB2005100589873A CN100509006C (zh) 2005-03-25 2005-03-25 治疗抑郁症的药物组合物及其制法
CN200510058987.3 2005-03-25
PCT/CN2005/001796 WO2006099783A1 (fr) 2005-03-25 2005-10-31 Préparation pharmaceutique pour le traitement de la dépression et méthode d'élaboration de ladite préparation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2005/001796 A-371-Of-International WO2006099783A1 (fr) 2005-03-25 2005-10-31 Préparation pharmaceutique pour le traitement de la dépression et méthode d'élaboration de ladite préparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/076,861 Continuation US9572827B2 (en) 2005-03-25 2013-11-11 Pharmaceutical composition for treating depression and method for preparation thereof

Publications (1)

Publication Number Publication Date
US20090232914A1 true US20090232914A1 (en) 2009-09-17

Family

ID=37014281

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/909,087 Abandoned US20090232914A1 (en) 2005-03-25 2005-10-31 Pharmaceutical composition for treating depression and method for preparation thereof
US14/076,861 Expired - Fee Related US9572827B2 (en) 2005-03-25 2013-11-11 Pharmaceutical composition for treating depression and method for preparation thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/076,861 Expired - Fee Related US9572827B2 (en) 2005-03-25 2013-11-11 Pharmaceutical composition for treating depression and method for preparation thereof

Country Status (26)

Country Link
US (2) US20090232914A1 (no)
EP (2) EP2110135B1 (no)
JP (1) JP2008533180A (no)
KR (1) KR20070116914A (no)
CN (1) CN100509006C (no)
AU (1) AU2005329710B2 (no)
BR (2) BR122017003461B1 (no)
CA (2) CA2601790C (no)
CY (1) CY1113666T1 (no)
DK (2) DK2110135T3 (no)
ES (2) ES2394609T3 (no)
HK (2) HK1111631A1 (no)
IL (1) IL186127A (no)
MX (1) MX2007011713A (no)
NO (1) NO338015B1 (no)
NZ (2) NZ562641A (no)
PL (1) PL1862158T3 (no)
PT (2) PT1862158E (no)
RU (1) RU2395293C2 (no)
SG (1) SG161214A1 (no)
SI (1) SI1862158T1 (no)
TR (1) TR200706524T1 (no)
TW (1) TW200904461A (no)
UA (2) UA92861C2 (no)
WO (1) WO2006099783A1 (no)
ZA (1) ZA200708156B (no)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311674A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
US20100310682A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions for treating anxiety
US20100311682A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Antimelancholic medicine prepared with jujube camp materials
US20100310683A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions for treating depression and anxiety
RU2486915C1 (ru) * 2012-03-01 2013-07-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент дезоксирибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI453027B (zh) * 2007-11-16 2014-09-21 Chi Yu Fen 主功效成分為大棗環腺苷單磷酸之藥物作為治療憂鬱症的用途
TWI394576B (zh) * 2007-11-20 2013-05-01 Chi Yu Fen 以人參、大棗為原料的治療憂鬱症的藥物組合物及其製法
TWI400078B (zh) * 2007-11-21 2013-07-01 Chi Yu Fen 以甘草、大棗為原料的治療憂鬱症的藥物組合物
RU2452505C2 (ru) * 2007-11-30 2012-06-10 Цзогуан ЧЖАН Фармацевтические композиции с механизмом многоцелевого рецепторного противодействия для лечения депрессии
RU2456014C2 (ru) * 2007-11-30 2012-07-20 Цзогуан ЧЖАН ЛЕКАРСТВЕННОЕ СРЕДСТВО ОТ МЕЛАНХОЛИИ, ПОЛУЧЕННОЕ С ИСПОЛЬЗОВАНИЕМ МАТЕРИАЛОВ С сАМР ЖУЖУБА
WO2009070917A1 (fr) * 2007-11-30 2009-06-11 Chi, Yu-Fen Composition pharmaceutique orale pour le traitement de la barythymie
WO2009070916A1 (fr) * 2007-11-30 2009-06-11 Chi, Yu-Fen Composition pharmaceutique pour le traitement de la dépression et son procédé de préparation
RU2449804C2 (ru) * 2007-11-30 2012-05-10 Цзогуан ЧЖАН Фармацевтические композиции для лечения депрессии и тревожного расстройства (варианты)
WO2009070923A1 (fr) * 2007-11-30 2009-06-11 Chi, Yu-Fen Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation
CN102038701B (zh) 2009-10-20 2012-06-27 张作光 芍药内酯苷的抗抑郁用途
CN102793760B (zh) * 2012-07-25 2015-04-22 青岛文创科技有限公司 一种改善帕金森病非运动障碍的药物组合物
SG11201501020WA (en) * 2012-08-15 2015-04-29 Chi Yu Fen Pharmaceutical composition for increasing content and availability of cyclic adenosine monophosphate in a body and the preparation thereof
CN107684614A (zh) * 2016-08-03 2018-02-13 临澧县第二人民医院 一种治疗抑郁症的中药组合物
CN115300547A (zh) * 2021-05-06 2022-11-08 邢禹贤 一药物组合物在制备用于治疗口臭、痔疮、白带腥臭及其组合之一的药品和保健品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2000800C1 (ru) * 1992-10-13 1993-10-15 Малое предпри тие "Европа" Способ получени экстракта корн солодки голой
US6395311B2 (en) * 1998-04-29 2002-05-28 Univera Pharmaceuticals, Inc. Multicomponent biological vehicle
US20040137087A1 (en) * 1997-12-12 2004-07-15 C.V. Technologies, Inc. Processes of making North American ginseng fractions, products containing them, and uses as immunomodulators
US20050079234A1 (en) * 2003-08-27 2005-04-14 Chiang Yang Chi Compositions comprising herbs and method for immunomodulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
CN1076608C (zh) * 1995-09-22 2001-12-26 刘增垣 治疗焦虑症的中药
US6083932A (en) 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
AU746072B2 (en) * 1998-01-13 2002-04-11 Rexall Sundown, Inc. St. John's wort and methyl donor composition and uses thereof
CN1070032C (zh) 1998-03-31 2001-08-29 山西中医学院 玫瑰晚茶及其制作方法
CN1259359A (zh) * 1998-11-06 2000-07-12 杨悦超 一种熊三仙药酒及其制备工艺
CN1183921C (zh) * 2000-03-06 2005-01-12 李世林 可通过头部穴位渗透法治疗抑郁症的药物
CN1122522C (zh) 2001-01-12 2003-10-01 王东桥 一种治疗抑郁型精神病的药物
CN1199682C (zh) * 2002-11-27 2005-05-04 北京中医药大学 一种四逆散的有效部位及其制备方法
CN1552333A (zh) * 2003-06-03 2004-12-08 张金铎 一种防治忧郁症的药物
CN1611232A (zh) * 2003-10-30 2005-05-04 北京欧纳尔生物工程技术有限公司 一种以抗疲劳、抗辐射、抗忧郁为主功效的药物组合物及其制法
JP2005278604A (ja) * 2004-03-31 2005-10-13 Daicho Kikaku:Kk 健康食品
CA2746663A1 (en) 2007-11-30 2009-06-11 Chi, Yu-Fen Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
BRPI0722185A2 (pt) 2007-11-30 2015-06-16 Yu Fen Chi Composições farmacêuticas para tratar ansiedade
MX2010005838A (es) 2007-11-30 2010-09-14 Yu Fen Chi Medicina antimelancolica preparada con materiales de camp de azufaifa.
ES2601510T3 (es) 2007-11-30 2017-02-15 Chi, Yu-Fen Composiciones farmacéuticas para tratar la depresión y la ansiedad

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2000800C1 (ru) * 1992-10-13 1993-10-15 Малое предпри тие "Европа" Способ получени экстракта корн солодки голой
US20040137087A1 (en) * 1997-12-12 2004-07-15 C.V. Technologies, Inc. Processes of making North American ginseng fractions, products containing them, and uses as immunomodulators
US6395311B2 (en) * 1998-04-29 2002-05-28 Univera Pharmaceuticals, Inc. Multicomponent biological vehicle
US20050079234A1 (en) * 2003-08-27 2005-04-14 Chiang Yang Chi Compositions comprising herbs and method for immunomodulation

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311674A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
US20100310682A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions for treating anxiety
US20100311682A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Antimelancholic medicine prepared with jujube camp materials
US20100310683A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions for treating depression and anxiety
US8889650B2 (en) * 2007-11-30 2014-11-18 Beijing Wonner Biotech, Ltd. Co. Antimelancholic medicine prepared with jujube camp materials
RU2486915C1 (ru) * 2012-03-01 2013-07-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент дезоксирибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия

Also Published As

Publication number Publication date
AU2005329710B2 (en) 2010-11-25
KR20070116914A (ko) 2007-12-11
UA92861C2 (ru) 2010-12-10
TR200706524T1 (tr) 2008-03-21
HK1111631A1 (en) 2008-08-15
CN1836687A (zh) 2006-09-27
BRPI0520141A2 (pt) 2009-08-25
SG161214A1 (en) 2010-05-27
PL1862158T3 (pl) 2013-04-30
EP2110135A2 (en) 2009-10-21
DK2110135T3 (da) 2014-03-31
EP1862158A4 (en) 2008-08-27
EP1862158B1 (en) 2012-08-29
PT2110135E (pt) 2014-04-07
RU2007135252A (ru) 2009-04-27
RU2395293C2 (ru) 2010-07-27
US9572827B2 (en) 2017-02-21
PT1862158E (pt) 2012-12-17
ES2394609T3 (es) 2013-02-04
EP1862158A1 (en) 2007-12-05
DK1862158T5 (da) 2013-03-04
IL186127A (en) 2015-09-24
CA2601790A1 (en) 2006-09-28
CA2821645A1 (en) 2006-09-28
MX2007011713A (es) 2008-01-28
SI1862158T1 (sl) 2013-02-28
CA2601790C (en) 2015-09-08
US20140065125A1 (en) 2014-03-06
DK1862158T3 (da) 2012-12-17
BR122017003461B1 (pt) 2018-01-16
NZ590712A (en) 2012-07-27
EP2110135B1 (en) 2014-01-01
EP2110135A3 (en) 2010-12-22
EP1862158B8 (en) 2013-04-03
WO2006099783A1 (fr) 2006-09-28
ES2455016T3 (es) 2014-04-14
HK1135338A1 (en) 2010-06-04
AU2005329710A1 (en) 2006-09-28
NZ562641A (en) 2012-05-25
TW200904461A (en) 2009-02-01
IL186127A0 (en) 2008-08-07
NO20074753L (no) 2007-12-20
JP2008533180A (ja) 2008-08-21
CA2821645C (en) 2016-08-09
CY1113666T1 (el) 2016-06-22
NO338015B1 (no) 2016-07-18
ZA200708156B (en) 2009-05-27
CN100509006C (zh) 2009-07-08
UA92739C2 (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
US9572827B2 (en) Pharmaceutical composition for treating depression and method for preparation thereof
EP2491934B1 (en) Use of albiflorin for anti-depression
CN102438630B (zh) 治疗抑郁症的药物组合物、制备方法及用途
KR100970739B1 (ko) 황련 추출물을 유효성분으로 함유하는 호흡기 질환의 예방및 치료용 조성물
KR20100106976A (ko) 우울증 및 불안 치료용 약학적 조성물
WO2011003226A1 (zh) 治疗抑郁症的药物组合物、制备方法及用途
US8889650B2 (en) Antimelancholic medicine prepared with jujube camp materials
AU2007361992B2 (en) Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
EP1352653A1 (en) Dihydrofuran cyclic tanshintones used in treating hyperammonemia and hepatic encephalopathy
EP3263114A1 (en) Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome
US20200113962A1 (en) Composition for preventing, alleviating or treating stress diseases, containing platycodon grandiflorum extract as active ingredient
KR102232330B1 (ko) 생강나무 잎 추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방, 치료, 또는 개선용 조성물
CN100546589C (zh) 虫草头孢菌粉抗心律失常有效部位的制备及其药物制剂
RU2456014C2 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВО ОТ МЕЛАНХОЛИИ, ПОЛУЧЕННОЕ С ИСПОЛЬЗОВАНИЕМ МАТЕРИАЛОВ С сАМР ЖУЖУБА
CN112402485A (zh) 植物提取物在抗产褥期精神综合症药物中的应用
Finney-Brown et al. Reviews of articles on medicinal herbs

Legal Events

Date Code Title Description
AS Assignment

Owner name: BEIJING WONNER BIOTECH LTD. CO., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZHANG, ZUOGUANG;REEL/FRAME:019845/0957

Effective date: 20070911

Owner name: CHI, YUH-FEN, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZHANG, ZUOGUANG;REEL/FRAME:019845/0957

Effective date: 20070911

Owner name: ZHANG, ZUOGUANG, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZHANG, ZUOGUANG;REEL/FRAME:019845/0957

Effective date: 20070911

AS Assignment

Owner name: BEIJING WONNER BIOTECH, LTD. CO., CHINA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE YUH-FEN CHI SHOULD READ YU-FEN CHI PREVIOUSLY RECORDED ON REEL 019845 FRAME 0957. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:ZHANG, ZUOGUANG;REEL/FRAME:028518/0280

Effective date: 20120706

Owner name: ZHANG, ZUOGUANG, CHINA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE YUH-FEN CHI SHOULD READ YU-FEN CHI PREVIOUSLY RECORDED ON REEL 019845 FRAME 0957. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:ZHANG, ZUOGUANG;REEL/FRAME:028518/0280

Effective date: 20120706

Owner name: CHI, YU-FEN, TAIWAN

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE YUH-FEN CHI SHOULD READ YU-FEN CHI PREVIOUSLY RECORDED ON REEL 019845 FRAME 0957. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:ZHANG, ZUOGUANG;REEL/FRAME:028518/0280

Effective date: 20120706

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION